Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis works to enhance its investor appeal ahead of its market debut next month. Its launch ambitions come as Novartis shareholders are widely expected to sign off on the Sandoz spin-off at an extraordinary general meeting on Friday.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles